-
1.发明申请
公开(公告)号：WO2007031865A3
公开(公告)日：2007-03-22
申请号：PCT/IB2006/002579
申请日：2006-09-18
Applicant: GLENMARK PHARMACEUTICALS LIMITED , SAWANT, Mangesh, Shivram , BISWAS, Maloyesh, Mathuresh , KHAN, Mubeen, Ahmed , SINHA, Sukumar , PRADHAN, Nitin, Sharad, Chandra
Inventor： SAWANT, Mangesh, Shivram , BISWAS, Maloyesh, Mathuresh , KHAN, Mubeen, Ahmed , SINHA, Sukumar , PRADHAN, Nitin, Sharad, Chandra
IPC: C07D211/90
Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.
-
2.发明申请POLYMORPHIC FORMS OF (S)-OMEPRAZOLE MAGNESIUM SALTS AND PROCESSES FOR THEIR PREPARATION 审中-公开（S） - 甲基镁盐的多晶形式及其制备方法
公开(公告)号：WO2007031845A2
公开(公告)日：2007-03-22
申请号：PCT/IB2006/002520
申请日：2006-09-13
Applicant: GLENMARK PHARMACEUTICALS LIMITED , KUMAR, Bobba Venkata Siva , KULKARNI, Pravin Bhalchandra , RAUT, Changdev Namdev , SURYAWANSHI, Anil Ganpat , PRADHAN, Nitin Sharad Chandra
Inventor： KUMAR, Bobba Venkata Siva , KULKARNI, Pravin Bhalchandra , RAUT, Changdev Namdev , SURYAWANSHI, Anil Ganpat , PRADHAN, Nitin Sharad Chandra
IPC: C07D401/12 , A61K31/44 , A61K31/4439 , A61P1/04
CPC classification number: C07D401/12
Abstract: Novel polymorphs of a magnesium salt of (S)-omeprazole trihydrate and processes for their preparation are disclosed. Also disclosed is a process for the preparation of an amorphous form of a magnesium salt of (S)-omeprazole. Pharmaceutical compositions containing the magnesium salts are also disclosed.
Abstract translation: 公开了（S） - 奥美拉唑三水合物的镁盐的新型多晶型物及其制备方法。 还公开了制备（S） - 奥美拉唑的无定形形式的镁盐的方法。 还公开了含有镁盐的药物组合物。
-
公开(公告)号：WO2007110734A1
公开(公告)日：2007-10-04
申请号：PCT/IB2007/000737
申请日：2007-03-23
Applicant: GLENMARK PHARMACEUTICALS LIMITED , CRASTO, Anthony, Melvin , JOSHI, Narendra, Shriram , PRADHAN, Nitin, Sharad, Chandra
IPC: C07D471/04 , C07D471/14
CPC classification number: C07D471/04 , C07D471/14
Abstract: The present invention provides novel intermediates of tadalafil and processes for their preparation. The present invention also provides for the preparation of tadalafil or a pharmaceutically acceptable salt or solvate thereof using the intermediates.
Abstract translation: 本发明提供了他达拉非的新型中间体及其制备方法。 本发明还提供了使用中间体制备他达拉非或其药学上可接受的盐或溶剂合物。
-
4.发明申请POLYMORPHIC FORMS OF (S)-OMEPRAZOLE MAGNESIUM SALTS AND PROCESSES FOR THEIR PREPARATION 审中-公开（S） - 咪唑镁盐的多晶型形式及其制备方法
公开(公告)号：WO2007031845A3
公开(公告)日：2007-05-18
申请号：PCT/IB2006002520
申请日：2006-09-13
Applicant: GLENMARK PHARMACEUTICALS LTD , KUMAR BOBBA VENKATA SIVA , KULKARNI PRAVIN BHALCHANDRA , RAUT CHANGDEV NAMDEV , SURYAWANSHI ANIL GANPAT , PRADHAN NITIN SHARAD CHANDRA
Inventor： KUMAR BOBBA VENKATA SIVA , KULKARNI PRAVIN BHALCHANDRA , RAUT CHANGDEV NAMDEV , SURYAWANSHI ANIL GANPAT , PRADHAN NITIN SHARAD CHANDRA
IPC: C07D401/12 , A61K31/44 , A61K31/4439 , A61P1/04
CPC classification number: C07D401/12
Abstract: Novel polymorphs of a magnesium salt of (S)-omeprazole trihydrate and processes for their preparation are disclosed. Also disclosed is a process for the preparation of an amorphous form of a magnesium salt of (S)-omeprazole. Pharmaceutical compositions containing the magnesium salts are also disclosed.
Abstract translation: 公开了（S） - 奥美拉唑三水合物镁盐的新多晶型物及其制备方法。 还公开了制备（S） - 奥美拉唑镁盐的无定形形式的方法。 还公开了含有镁盐的药物组合物。
-
公开(公告)号：WO2006129190A1
公开(公告)日：2006-12-07
申请号：PCT/IB2006/001471
申请日：2006-06-02
Applicant: GLENMARK PHARMACEUTICALS LIMITED , PRADHAN, Nitin, Sharad, Chandra , PURUSHOTHAM, Vandanapu, Loka, Appala , NAIK, Samir, Jaivant , SRIDHARAN, Ramasubramanian
Inventor： PRADHAN, Nitin, Sharad, Chandra , PURUSHOTHAM, Vandanapu, Loka, Appala , NAIK, Samir, Jaivant , SRIDHARAN, Ramasubramanian
IPC: C07D209/16 , C07F7/08 , A61K31/4045 , A61P25/00
CPC classification number: C07D295/26 , C07D209/16 , C07D209/30 , C07F7/1856 , C07F7/1892 , Y02P20/55
Abstract: A process for preparing an intermediate of almotriptan is disclosed, the process comprising the step of Heck coupling a 2-halo aniline derivative of Formula (I): wherein X is a halogen with a protected butynol compound of the general formula (III) wherein Prot can be the same or different and is a suitable protecting group, to provide a protected indole derivative of Formula (II).
Abstract translation: 公开了制备阿莫曲坦的中间体的方法，该方法包括将式（I）的2-卤代苯胺衍生物Heck偶联的步骤：其中X是具有通式（III）的保护的丁炔化合物的卤素，其中Prot 可以相同或不同，并且是合适的保护基，以提供式（II）的受保护的吲哚衍生物。
-
Patent Agency Ranking6.发明申请PROCESS FOR THE PREPARATION OF N-[1-(S)-ETHOXYCARBONYL-1-BUTYL]-(S)-ALANINE-DMT COMPLEX AND ITS USE IN THE PREPARATION OF PERINDOPRIL 审中-公开制备N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 缬氨酸-DMT复合物的方法及其在制备帕金森中的应用
公开(公告)号：WO2007085933A3
公开(公告)日：2009-05-07
申请号：PCT/IB2007000150
申请日：2007-01-23
Inventor： JOSHI NARENDRA SHRIRAM , PRADHAN NITIN SHARAD CHANDRA
IPC: A61K31/40 , C07D209/00 , C07D209/42
CPC classification number: C07D251/34 , C07K5/06026
Abstract: A compound N-[l-(S)-ethoxycarbonyl-l-butyl]-(S)-alanine-DMT complex of Formula (II) is provided. Also provided is a process for the preparation of N-[l-(S)-ethoxycarbonyl-l-butyl]-(S)- alanine-DMT complex and its use in preparing perindopril or a pharmaceutically acceptable salt thereof.
Abstract translation: 提供式（II）的化合物N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 丙氨酸-DMT络合物。 还提供了制备N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 丙氨酸-DMT复合物的方法及其在制备培哚普罗或其药学上可接受的盐中的用途。
-
7.发明申请IMPROVED PROCESS FOR THE PREPARATION OF AN OPTICALLY ACTIVE 5H-PYRROLO [3,4-B] PYRAZINE DERIVATIVE 审中-公开改进的制备光学活性5H-吡咯并[3,4-B]吡嗪衍生物的方法
公开(公告)号：WO2007083188A2
公开(公告)日：2007-07-26
申请号：PCT/IB2006/003801
申请日：2006-12-29
Applicant: GLENMARK PHARMACEUTICALS LIMITED , PILLAI, Biju, Kumar, Gopinathen , ARJUNAN, Sankar , PRADHAN, Nitin, Sharad, Chandra , JOSHI, Narendra, Shriram
Inventor： PILLAI, Biju, Kumar, Gopinathen , ARJUNAN, Sankar , PRADHAN, Nitin, Sharad, Chandra , JOSHI, Narendra, Shriram
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: A substantially pure dextrorotatory isomer of zopiclone or a pharmaceutically acceptable salt thereof and crystalline forms thereof are provided. Also provided is a process for its preparation and pharmaceutical compositions containing same.
Abstract translation: 提供了佐匹克隆的基本上纯的右旋异构体或其药学上可接受的盐及其晶体形式。 还提供了其制备方法和含有它的药物组合物。
-
8.发明申请POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF 审中-公开氯代吡啶氯化物的多晶型及其制备方法
公开(公告)号：WO2007031865A2
公开(公告)日：2007-03-22
申请号：PCT/IB2006002579
申请日：2006-09-18
Applicant: GLENMARK PHARMACEUTICALS LTD , SAWANT MANGESH SHIVRAM , BISWAS MALOYESH MATHURESH , KHAN MUBEEN AHMED , SINHA SUKUMAR , PRADHAN NITIN SHARAD CHANDRA
Inventor： SAWANT MANGESH SHIVRAM , BISWAS MALOYESH MATHURESH , KHAN MUBEEN AHMED , SINHA SUKUMAR , PRADHAN NITIN SHARAD CHANDRA
IPC: C07D211/90
CPC classification number: C07D211/90
Abstract: Processes for the purification of lercanidipine hydrochloride are provided which uses a binary system of an alcohol-containing solvent such as methanol and an aliphatic ester-containing solvent such as isopropyl acetate. Processes for the preparation of substantially amorphous lercanidipine hydrochloride are also provided. Also provided is lercanidipine hydrochloride substantially in polymorph form V.
Abstract translation: 提供盐酸乐卡地平的纯化方法，其使用含醇溶剂如甲醇和含脂肪酸酯的溶剂如乙酸异丙酯的二元体系。 还提供了制备基本上无定形的乐卡尼平盐酸盐的方法。 还提供了基本上呈多晶型形式的盐酸氯卡地平
-
9.发明申请PROCESS FOR THE PREPARATION OF N-[1-(S)-ETHOXYCARBONYL-1-BUTYL]-(S)-ALANINE-DMT COMPLEX AND ITS USE IN THE PREPARATION OF PERINDOPRIL 审中-公开制备N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 缬氨酸-DMT复合物的方法及其在制备帕金森中的应用
公开(公告)号：WO2007085933A2
公开(公告)日：2007-08-02
申请号：PCT/IB2007/000150
申请日：2007-01-23
Applicant: GLENMARK PHARMACEUTICALS LIMITED , JOSHI, Narendra, Shriram , PRADHAN, Nitin, Sharad, Chandra
IPC: A61K31/53
CPC classification number: C07D251/34 , C07K5/06026
Abstract: A compound N-[l-(S)-ethoxycarbonyl-l-butyl]-(S)-alanine-DMT complex of Formula (II) is provided. Also provided is a process for the preparation of N-[l-(S)-ethoxycarbonyl-l-butyl]-(S)- alanine-DMT complex and its use in preparing perindopril or a pharmaceutically acceptable salt thereof.
Abstract translation: 提供式（II）的化合物N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 丙氨酸-DMT络合物。 还提供了制备N- [1-（S） - 乙氧基羰基-1-丁基] - （S） - 丙氨酸-DMT复合物的方法及其在制备培哚普罗或其药学上可接受的盐中的用途。
-
10.发明申请ESOMEPRAZOLE STRONTIUM SALT, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME 审中-公开异喹诺酮盐，其制备方法和含有其的药物组合物
公开(公告)号：WO2006120520A1
公开(公告)日：2006-11-16
申请号：PCT/IB2006/001109
申请日：2006-05-02
Applicant: GLENMARK PHARMACEUTICALS LIMITED , BHIRUD, Shekhar Bhaskar , PRADHAN, Nitin Sharad Chandra , KUMAR, Bobba Venkata Siva , KULKARNI, Pravin Bhalchandra
Inventor： BHIRUD, Shekhar Bhaskar , PRADHAN, Nitin Sharad Chandra , KUMAR, Bobba Venkata Siva , KULKARNI, Pravin Bhalchandra
IPC: C07D401/12 , A61K31/44 , A61P1/04
CPC classification number: C07D401/12
Abstract: A strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.
Abstract translation: 提供了艾美拉唑的锶盐。 还提供了制备艾美拉唑锶盐的方法，包括使埃索美拉唑游离碱或埃索美拉唑钠盐，钾盐或锂盐与一种或多种溶剂中的锶来源反应。
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.012 seconds)
